Intrasense and its partners 12 Sigma Technologies and Quantib presented several products leveraging the company’s Myrian® technology at RSNA 2018, the industry’s leading radiology conference.
Bringing artificial intelligence to clinical practiceIntrasense presented its innovative solutions and showcased two of its partners, 12 Sigma Technologies and Quantib, at the RSNA annual meeting – the largest global radiology event for professionals from 136 countries, held November 25 - 30, 2018 in Chicago (United States). The company’s partners use artificial intelligence for their clinical applications developed from Intrasense’s Myrian® Studio technology on the Myrian® platform:
- σ-Discover Lung Nodule, an entirely new application developed by 12 Sigma Technologies to detect lung cancer, providing extremely fine analysis of pulmonary nodules.
- Quantib™ ND, an advanced neurology imaging application designed by Quantib, a spin-off from the Erasmus University Medical Center in Rotterdam (Netherlands). Quantib™ ND integrates a variety of hi-tech tools for analyzing brain MRI scans.
Myrian® Studio, a springboard for innovationAt RSNA, Intrasense encouraged innovative development in imaging, announcing the winners of the Myrian® Studio Challenge, which recognizes and supports startups and researchers working on particularly innovative projects. The goal is to help users leverage Myrian® to industrialize and bring their solutions to market quickly.
Myrian® used during a workshop focusing on the reference PI-RADS 2 methodOnce again this year, renowned international professors chose to use the Myrian® XP-Prostate application to train 1,000 radiologists on the PI-RADS 2 reference diagnostics method (Prostate Imaging Reporting and Data System).
The Prostate MRI workshop showed participants how to perform case analyses using the PI-RADS 2 MRI method, directly integrated into the Myrian® XP-Prostate module.
This method optimizes patient care and follow-up and enables doctors to quantify the probability of prostate cancer in patients, while improving detection, and identifying benign pathologies more effectively.
“We are very proud that Myrian® was chosen again this year for the prestigious training workshop, with its very large audience. Since it was created, Myrian® XP‑Prostate has integrated the PI-RADS score and instantly provides information that is particularly useful for doctors,” says Frédéric HENAFF, Product Director at Intrasense.